Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency

[madman]

In summary, TTh in the physiologic range in men with TD imparts great benefits to men’s health as demonstrated by the improvement in glycometabolic and cardiometabolic function, improved sexual function, body composition, and BMD, amelioration of anemia, and improvement in overall quality of life.

 

[madman]

https://www.sciencedirect.com/science/article/pii/S2050052117301191

 

[madman]

Figure 1. Testosterone, directly or through conversion to 5α-dihydrotestosterone or estradiol, modulates multipotent stem cell metabolism and function to promote differentiation to progenitor cells for muscle, endothelium, bone, and red blood cells. DHT = 5α-dihydrotestosterone; E2 = estradiol; T = testosterone. From Carruthers M, Trinick TR, Jankowska E, et al. Are the adverse effects of glitazones linked to induced testosterone deficiency? Originally published and reprinted from BioMed Central from Carruthers M, Trinick TR, Jankowska E, Traish AM. Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovasc Diabetol 2008;7:30.333 Figure 1 is available in color at www.smr.jsexmed.org.

 

[madman]

Figure 2. Changes in waist circumference in testosterone-treated and untreated (control) groups. Changes (yellow bars) were adjusted for baseline differences between testosterone-treated (green bars) and untreated control (red bars) groups. From Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther 2017;22:414–433.155
Reprinted with permission. Figure 2 is available in color at www.smr.jsexmed.org.

 

[madman]

Figure 3. Changes in fasting blood glucose and HbA1c in testosterone-treated and untreated (control) groups. Panel A shows changes in glucose levels (yellow bars) adjusted for baseline differences between testosterone-treated (green bars) and untreated control (red bars) groups. Panel B shows changes in HbA1c (yellow bars) adjusted for baseline differences between testosterone-treated (green bars) and untreated control (red bars) groups. HbA1c = glycated hemoglobin. From Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther 2017;22:414–433.155
Reprinted with permission. Figure 3 is available in color at www.smr.jsexmed.org.

 

[madman]

Figure 4. Changes (yellow bars) in lipid profile in testosterone-treated (green bars) and untreated control (red bars) groups. Panel A shows changes in total cholesterol adjusted for baseline differences between testosterone-treated and untreated control groups. Panel B shows changes in LDL cholesterol adjusted for baseline differences between testosterone-treated and untreated control groups. Panel C shows changes in HDL cholesterol adjusted for baseline differences between testosterone-treated and untreated control groups. Panel D shows changes in triglycerides adjusted for baseline differences between testosterone-treated and untreated control groups. HDL = high-density lipoprotein; LDL = low-density lipoprotein. From Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther 2017;22:414–433.155
Reprinted with permission. Figure 4 is available in color at www.smr.jsexmed.org.

 

[madman]

Figure 5. The primary outcome of the Sexual Function Trial was the change from baseline in the score for sexual activity on the PDQ-Q4 (range = 0–12, with higher scores indicating more activity). PDQ-Q4 = question 4 of the Psychosexual Daily Questionnaire. From Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med 2016;374;611–624.232
Reprinted with permission. Figure 5 is available in color at www.smr.jsexmed.org.

 

[madman]

Figure 6. Effects of testosterone therapy on erectile function. Changes in IIEF-EF score in testeosterone-treated and untreated propensity-matched groups during 8-year follow-up period. IIEF-EF = International Index of Erectile Function erectile function domain. From Haider KS, Haider A, Doros G, et al. Long-term testosterone therapy improves urinary and sexual function and quality of life in men with hypogonadism: results from a propensity-matched subgroup of a controlled registry study. J Urol https://doi.org/10.1016/j.juro 2017.07.039.178
Reprinted with permission.